文献速递血栓与止血

重组猪FVIII治疗获得性血友病A出血:单中心18例队列研究

Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort.
PubMed 文献 · Blood Adv · 2020-01-01

本研究在单中心使用基于算法的重组猪FVIII(rpFVIII)治疗18例获得性血友病A(AHA)患者的出血,剂量显著低于FDA推荐剂量。数据显示暴露前抗猪Bethesda滴度不能可靠预测临床反应,且与抗人Bethesda滴度不相关; upfront使用rpFVIII较挽救治疗初始止血所需总剂量更低。研究在既往系列基础上新增14例患者验证了该低剂量算法。

要点

  • rpFVIII可按算法以低于FDA推荐的剂量有效治疗AHA出血。
  • 暴露前抗猪Bethesda滴度不能可靠预测rpFVIII临床反应。
  • upfront使用rpFVIII较挽救治疗初始止血总剂量更低。

核心结论

  • 基于算法的rpFVIII低剂量方案可成功治疗AHA患者出血,且暴露前抗猪Bethesda滴度不能可靠预测临床反应。

研究设计与样本

  • 单中心、18例患者队列研究,使用基于算法的rpFVIII治疗AHA出血,较既往报告系列新增14例患者。

主要发现

  • rpFVIII以显著低于FDA推荐的剂量成功治疗18例AHA患者出血。
  • 暴露前抗猪Bethesda滴度不能可靠预测rpFVIII临床反应,且与抗人Bethesda滴度不相关。
  • upfront使用rpFVIII较作为挽救治疗时初始出血缓解所需总rpFVIII用量更低。

关键数值与推荐

  • rpFVIII(Obizur)于2014年获FDA批准用于AHA出血治疗,可实验室监测FVIII活性水平。
  • 本研究算法剂量显著低于当前FDA推荐剂量。

临床怎么用

  • AHA出血可考虑使用基于算法的rpFVIII低剂量方案,并监测FVIII活性水平。
  • 不应仅凭暴露前抗猪Bethesda滴度预测rpFVIII疗效。
  • upfront使用rpFVIII可能减少初始止血所需总剂量。

局限性

  • 单中心、小样本(18例)队列研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired hemophilia A (AHA) is a rare bleeding disorder in which acquired autoantibodies to endogenous factor VIII (FVIII) decrease FVIII activity and lead to a bleeding phenotype. A substantial majority of individuals who develop AHA present with severe bleeding. Effective treatment requires both immunosuppressive therapy and prompt hemostatic treatment. Bleeding is commonly treated with bypassing agents (BPAs) such as recombinant activated FVII (rFVIIa) or activated prothrombin complex concentrates Disadvantages to BPAs include the inability to monitor response with standard laboratory assays, inconsistent hemostatic efficacy, and thrombosis. Recombinant porcine FVIII (rpFVIII: Obizur, Baxter, Deerfield, IL) was approved by the US Food and Drug Administration (FDA) for bleed treatment in AHA in 2014, and has the advantage of laboratory monitoring of FVIII activity levels and known hemostatic efficacy in the presence of anti-human FVIII inhibitors and after failure of BPAs. Using an algorithm-based approach, rpFVIII has been used to successfully treat 18 patients with AHA at our center with substantially lower doses than the current FDA-recommended dosing. Additionally, data from our cohort show that the preexposure anti-porcine Bethesda titer does not reliably predict the clinical response to rpFVIII treatment and is not correlated with the anti-human Bethesda titer. We also present data showing lower total rpFVIII use for initial bleed resolution when rpVIII is used upfront, as compared with use as rescue therapy. We validated our dosing algorithm, which uses much lower than FDA-recommended doses with 14 more patients than in our previously reported patient series.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ellsworth P, Chen SL, Kasthuri RS, et al. Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort. Blood Adv. 2020. PMID: 33351122. doi:10.1182/bloodadvances.2020002977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。